Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics appoints new chief commercial officer

Francesco Maria Lavino joins to support commercialisation of its new antibiotic

Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for community-acquired bacterial pneumonia.

Lavino joins the Austrian clinical-stage biopharma firm from Merck & Co (MSD), bringing nearly two decades of pharmaceutical sales and marketing experience with expertise in anti-infective medications.

He said: “Nabriva Therapeutics is poised to introduce what is potentially the first new class of antibiotics for systemic human use in nearly two decades.

“I am looking forward to working with the management team to address serious medical needs in lung, skin and potentially other types of infections.”

Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals. He has also held roles at UCB Pharma and 3M in Italy.

Colin Broom, chief executive officer of Nabriva, said: “Francesco has the right experience and leadership qualities to build out a fully integrate commercial team and hospital field force in the US, and I am delighted to welcome him as part of our team.”

20th July 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics